Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech Inc (NQ: KRYS )

120.48 +3.09 (+2.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,342
Open 117.39
Bid (Size) 105.00 (2)
Ask (Size) 191.36 (2)
Prev. Close 117.39
Today's Range 116.36 - 120.79
52wk Range 49.17 - 123.84
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga

Performance

YTD
+52.06%
+52.06%
1 Month
+43.43%
+43.43%
3 Month
+54.18%
+54.18%
6 Month
+57.47%
+57.47%
1 Year
+104.62%
+104.62%

More News

Read More
Why Shares of Krystal Biotech Are Rising Monday
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
Via Benzinga
2 Risky Stocks That Could Soar in 2023
Via The Motley Fool
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
Via Benzinga
Recap: Krystal Biotech Q3 Earnings
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Via InvestorPlace
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International
Via Benzinga
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.